Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 2/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.43 |
| ▸ | ANPEP | P15144 | 2/20 | 0.43 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.43 |
| ▸ | ACP3 | P15309 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13879583 | 1.00 | MMP13 (0.47) | MMP13KEAP1ANPEPERAP1TDP1 | |
| SCHEMBL6763477 | 0.89 | MMP12 (0.54) | MMP13HDAC1HDAC2FFAR1 | |
| SCHEMBL1274725 | 0.88 | HDAC3 (0.47) | MMP13TDP1SLC6A3HDAC3MAPK1 | |
| SCHEMBL18943248 | 0.86 | TRPA1 (0.51) | TDP1SLC6A3HDAC3MAPK1ADRA1A | |
| SCHEMBL18942747 | 0.86 | TRPA1 (0.51) | TDP1SLC6A3HDAC3MAPK1ADRA1A | |
| SCHEMBL18943238 | 0.85 | TRPA1 (0.54) | SLC6A3HDAC3MAPK1ADRA1AHDAC4 | |
| SCHEMBL18942752 | 0.85 | TRPA1 (0.54) | SLC6A3HDAC3MAPK1ADRA1AHDAC4 | |
| SCHEMBL3459118 | 0.85 | TRPA1 (0.54) | SLC6A3HDAC3MAPK1ADRA1AHDAC4 | |
| SCHEMBL24726829 | 0.82 | PTGIR (0.45) | CYP3A4CYP2D6SMN1; SMN2TRPA1TSHR | |
| SCHEMBL13258072 | 0.80 | TAAR1 (0.42) | MMP13FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1137690-B2 | PEG-BASED MACROMONOMERS, CHEMICALLY INERT POLYMERS PREPARED THEREFROM AND THE USE OF THESE POLYMERS FOR ORGANIC SYNTHESIS AND ENZYME REACTIONS | CARLSBERG AS (DK) | 2007-01-24 | — | — | EP | claimed |
| EP-1137690-B1 | PEG-BASED MACROMONOMERS, CHEMICALLY INERT POLYMERS PREPARED THEREFROM AND THE USE OF THESE POLYMERS FOR ORGANIC SYNTHESIS AND ENZYME REACTIONS | CARLSBERG AS (DK) | 2004-11-10 | — | — | EP | claimed |
| EP-1137690-A2 | PEG-BASED MACROMONOMERS, CHEMICALLY INERT POLYMERS PREPARED THEREFROM AND THE USE OF THESE POLYMERS FOR ORGANIC SYNTHESIS AND ENZYME REACTIONS | Carlsberg A/S (DK) | 2001-10-04 | — | — | EP | claimed |
| WO-2000018823-A2 | PEG-BASED MACROMONOMERS, CHEMICALLY INERT POLYMERS PREPARED THEREFROM AND THE USE OF THESE POLYMERS FOR ORGANIC SYNTHESIS AND ENZYME REACTIONS | CARLSBERG A/S (DK) | 2000-04-06 | — | — | WO | claimed |
| CN-118125919-A | Preparation method of conjugated triene compound | 华南理工大学 | 2024-06-04 | — | — | CN | disclosed |
| CN-116829537-A | Process for preparing prostaglandin analogues supplied with nitric oxide | 尼科斯股份有限公司 | 2023-09-29 | — | — | CN | disclosed |
| CN-111484472-B | Process for preparing alkylnitriles | 中国科学院上海有机化学研究所 | 2023-07-07 | — | — | CN | disclosed |
| EP-4112599-A1 | KEY INTERMEDIATE FOR SYNTHESIZING PROSTAGLANDIN COMPOUNDS AND PREPARATION METHOD THEREFOR | SHENZHEN CATALYS TECHNOLOGY CO., LTD. (CN) | 2023-01-04 | — | — | EP | disclosed |
| WO-2022057734-A1 | KEY INTERMEDIATE FOR SYNTHESIZING PROSTAGLANDIN COMPOUNDS AND PREPARATION METHOD THEREFOR | 凯特立斯（深圳）科技有限公司 | 2022-03-24 | — | — | WO | disclosed |
| US-20210340107-A1 | NRF2 ACTIVATOR | BIOGEN MA INC. | 2021-11-04 | — | — | US | disclosed |
| EP-3875450-A1 | NRF2 ACTIVATOR | Biogen MA Inc. (US) | 2021-09-08 | — | — | EP | disclosed |
| EP-3562816-B1 | NRF2 ACTIVATOR | BIOGEN MA INC (US) | 2021-01-20 | — | — | EP | disclosed |
| EP-0295056-B1 | ANTI-INFLAMMATORY FURANONES | ALLERGAN, INC (US) | 1992-08-05 | — | — | EP | disclosed |
| US-5134128-A | Immunosuppressive and antiproliferative activity for psoriasis and calcium homeostasis | ALLERGAN, INC. (US) | 1992-07-28 | — | — | US | disclosed |
| EP-0402646-A1 | Retroviral protease inhibiting compounds | ABBOTT LABORATORIES (US) | 1990-12-19 | — | — | EP | disclosed |
| EP-0295056-A1 | Anti-inflammatory furanones | ALLERGAN, INC (US) | 1988-12-14 | — | — | EP | disclosed |
| EP-0046033-B1 | METHOD FOR ASYMMETRIC EPOXIDATION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 1986-10-15 | — | — | EP | disclosed |
| US-4594439-A | Resolution of chiral carbinol having aliphatic unsaturation | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JR. UNIVERSITY (US) | 1986-06-10 | — | — | US | disclosed |
| US-4471130-A | SELECTIVE STEREOISOMERS BY REACTING AN ALKENOL AND HYDROPEROXIDE USING A TRANSITION METAL ALKOKIDE CATALYST | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 1984-09-11 | — | — | US | disclosed |
| EP-0046033-A1 | Method for asymmetric epoxidation | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 1982-02-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210340107-A1 | NRF2 ACTIVATOR | NFE2L2, KEAP1, NQO1 | MMP13 4580/4885KEAP1 2/4885ANPEP 4659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.